Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tissue Regenix Group (FRA:LSW) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Tissue Regenix Group Days Sales Outstanding Related Terms
Tissue Regenix Group Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LSW vs VRTX, REGN, ALNY: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Tissue Regenix Group's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's Days Sales Outstanding falls into.
Tissue Regenix Group Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group (FRA:LSW) has a Days Sales Outstanding of 53.84 as of Jun. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Tissue Regenix Group and its competitors. This is near median its historical median of 55.46. Over the past decade, Tissue Regenix Group's Days Sales Outstanding has ranged from 41.79 to 146.00.
Is Tissue Regenix Group's Days Sales Outstanding too high?
Tissue Regenix Group's current Days Sales Outstanding of 53.84 is near median its 10-year median of 55.46. Over the past 10 years, this metric has ranged from a low of 41.79 to a high of 146.00. The Biotechnology industry median Days Sales Outstanding is 68.64. Tissue Regenix Group's value of 53.84 is 21.6% below this industry median. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Days Sales Outstanding compare to VRTX and REGN?
Tissue Regenix Group's Days Sales Outstanding of 53.84 can be compared against companies in the Biotechnology industry. The industry median Days Sales Outstanding is 68.64. Tissue Regenix Group's value of 53.84 is 21.6% below this benchmark. Historically, Tissue Regenix Group's own Days Sales Outstanding has ranged from 41.79 to 146.00 over the past decade. While the company's 10-year median is 55.46 vs. the industry median of 68.64, Tissue Regenix Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.64, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Regenix Group's current Days Sales Outstanding of 53.84 is 21.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Tissue Regenix Group and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current Days Sales Outstanding is 53.84, which is near median its own 10-year median of 55.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Days Sales Outstanding of 53.84. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Days Sales Outstanding is 53.84, which is near median its 10-year median of 55.46 and 21.6% below the Biotechnology industry median of 68.64. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Days Sales Outstanding is 53.84 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
Days Sales Outstanding: 53.84 (near median its 10-year median of 55.46)
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
Industry Position: 21.6% below the Biotechnology median
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
